Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...
TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Patterns of Complementary Medicine Utilization in Patients With Breast Cancer and Colorectal Cancer: A Cross-Sectional Study at a Tertiary Referral Hospital in Yogyakarta, Indonesia A partitioned ...
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial A Markov model was created with six ...
Please provide your email address to receive an email when new articles are posted on . The cost-effectiveness of sacubitril/valsartan was intermediate in patients with HF with mildly reduced EF. The ...
Discover how Long Run Incremental Cost (LRIC) affects business decisions and pricing strategy with insights on cost prediction, investment impact, and financial control.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results